FDA: Omontys injection pulled from market

FDA: omontys injection pulled from market
Affymax Inc. of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited of Deerfield, Ill., have voluntarily recalled all lots of Omontys Injection, used to treat anemia in adult dialysis patients, following reports of serious and fatal hypersensitivity reactions, according to a safety recall issued by the U.S. Food and Drug Administration.

(HealthDay)—Affymax Inc. of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited of Deerfield, Ill., have voluntarily recalled all lots of Omontys Injection, used to treat anemia in adult dialysis patients, following reports of serious and fatal hypersensitivity reactions, according to a safety recall issued by the U.S. Food and Drug Administration.

The recall comes after reports of some patients experiencing serious and fatal hypersensitivity reactions following receipt of a first dose of Omontys, given by intravenous injection. The reactions, which occured within 30 minutes following the dose, were not reported following subsequent dosing or in patents who had completed their dialysis session.

The FDA has received 19 reports of anaphylaxis from dialysis centers around the United States, three of which resulted in death. Other patients required rapid medical intervention or hospitalization. Reports included patients who were able to be resuscitated.

"Due to the severity of the , we want to be certain that stop using Omontys," Howard Sklamberg, J.D., director of the Office of Compliance at the FDA's Center for Drug Evaluation and Research, said in a statement. "Americans deserve medications that are safe, effective, and of the highest quality. We are investigating the products and facilities associated with this recall and will provide updates as we learn more."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA: Zofran 32-mg dose pulled from market

Dec 06, 2012

(HealthDay)—The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according ...

FDA: Ameridose issues voluntary recall of all products

Nov 02, 2012

(HealthDay)—Ameridose, a Massachusetts-based manufacturer of sterile injectable products and oral syringes, is undergoing a voluntary recall of all unexpired products in circulation, according to an Oct. ...

Baxter issues urgent recall of Heparin

Jan 26, 2008

Baxter Healthcare has issued an urgent U.S. recall of nine lots of the injectable blood thinner heparin after reports of adverse patient reactions.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

14 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments